HALEOS LABS LIMITED

HALEOS LABS LIMITED

Haleos Labs Limited has informed the Exchange about obtaining a Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming compliance with dematerialization actions for the period from 01/07/2026 to 30/09/2026.

HALEOS LABS LIMITED

HALEOS LABS LIMITED has submitted the Exchange a copy Scrutinizer's report of Annual General Meeting held on September 30, 2026. The company has informed the Exchange regarding voting results, with all resolutions passed with requisite majority.

HALEOS LABS LIMITED

Haleos Labs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026. The meeting was conducted through Video conference and 58 members attended the meeting through VC. The company has made all feasible efforts to facilitate their participation and voting on the business items of the Meeting.

HALEOS LABS LIMITED

Haleos Labs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

HALEOS LABS LIMITED

HALEOS LABS LIMITED has informed about the successful USFDA inspection of its material subsidiary, Mahi Drugs Private Limited, with zero Form 483 observations, reflecting the company's commitment to regulatory compliance and quality.

HALEOS LABS LIMITED

Haleos Labs Limited has informed the Exchange regarding the Annual Report (Weblink) and the 20th Annual General Meeting (AGM) scheduled to be held on September 30, 2026. Shareholders are requested to update their email id and other KYC details to receive important communications.

HALEOS LABS LIMITED

HALEOS LABS LIMITED has informed the Exchange about Copy of Newspaper Publication for AGM notice.

HALEOS LABS LIMITED

Haleos Labs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026.

HALEOS LABS LIMITED

Haleos Labs Limited has informed the Exchange about the Events Calendar related to the 20th Annual General Meeting (AGM) scheduled to be held on September 30, 2026, through Video Conferencing/OAVM. The company has also appointed Central Depository Services (India) Ltd as the authorized agency for e-voting and Mr. C. Sudhir Babu as the Scrutinizer for conducting the remote e-voting process.

HALEOS LABS LIMITED

HALEOS LABS LIMITED has announced the record date for the purpose of dividend as 23-Sep-2026. The dividend will be paid within 30 days from the date of approval by the Shareholders, by way of credit to the respective bank accounts of the shareholders of the company.

HALEOS LABS LIMITED

Haleos Labs Limited has submitted the Exchange a copy of the Scrutinizers report of Postal Ballot. The company has informed the Exchange regarding voting results. Resolutions Nos. 1, 3 and 4 have been passed by the shareholders with the requisite majority, however, Resolution NO. 2, pertaining to the approval for payment of managerial remuneration to the Executive Directors, did not receive the requisite majority and accordingly, was not approved by the shareholders through the Postal Ballot process.

HALEOS LABS LIMITED

Haleos Labs Limited has informed the Exchange regarding 'Communication To Shareholders (TDS Related)' regarding tax deduction on dividend.

HALEOS LABS LIMITED

HALEOS LABS LIMITED has informed the Exchange about the publication of financial results in newspapers, as per Regulation 47(1)(b) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

HALEOS LABS LIMITED

HALEOS LABS LIMITED has informed the Exchange regarding 'Update (Material Subsidiary)' regarding the appointment of Cost Auditors and Nominee Director for its material subsidiary, Mis Mahi Drugs Private Limited.

HALEOS LABS LIMITED

Haleos Labs Limited has informed the Exchange regarding the reappointment of two independent directors, Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam, for a second consecutive term of 5 years, subject to shareholder approval.

HALEOS LABS LIMITED

Haleos Labs Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 6,782.97 lakhs and net profit at Rs. 323.78 lakhs. The company has also announced the re-appointment of two independent directors for a second term of 5 years and the revision of managerial remuneration for its managing director.

HALEOS LABS LIMITED

Haleos Labs Limited has informed the Exchange about the publication of a newspaper advertisement for a postal ballot, which includes the reappointment of a whole-time director, payment of managerial remuneration, and approval of material related party transactions.

HALEOS LABS LIMITED

HALEOS LABS LIMITED has informed the Exchange regarding Notice of Postal Ballot for seeking approval of the Members of the Company, for the following matter: reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director of the Company, payment of managerial remuneration to Executive Directors, Material Related Party Transactions of the Company and its Subsidiary for the year 2026-27.

HALEOS LABS LIMITED

Haleos Labs Limited has informed the Exchange regarding 'Events Calendar (Postal Ballot)' for seeking shareholders' approval through postal ballot for reappointment of a Whole-time Director, managerial remuneration, and material related party transactions.

HALEOS LABS LIMITED

HALEOS LABS LIMITED has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming compliance with dematerialization actions for the period from 01/04/2026 to 30/06/2026.